慢性中性粒细胞白血病与非典型慢性髓性白血病:2024年诊断、遗传学、风险分层与管理更新
本文综述了慢性中性粒细胞白血病(CNL)与非典型慢性髓性白血病(aCML)的2022年WHO和ICC诊断标准、分子特征、预后风险模型及治疗选择。CNL以CSF3R T618I突变(>80%)为特征,aCML常伴ASXL1、SETBP1等突变;两者白血病转化率分别约10-25%和30-40%,总生存期分别为15-31个月和12-20个月。治疗为风险驱动和对症处理,尚无标准方案,造血干细胞移植是唯一可能治愈的手段。
要点
- CNL诊断需白细胞≥25×10⁹/L、中性粒细胞≥80%且循环前体细胞<10%、无病态造血及CSF3R激活突变。
- ICC标准中CSF3R突变病例的白细胞阈值降至≥13×10⁹/L,aCML需病态粒细胞生成且循环髓系前体细胞≥10%。
- Mayo Clinic CNL风险模型:血小板<160×10⁹/L(2分)、白细胞>60×10⁹/L(1分)、ASXL1突变(1分),区分低危(0-1分)与高危(2-4分)。
核心结论
- CNL和aCML均为罕见的BCR::ABL1阴性髓系肿瘤,白血病转化率高且总生存期差,治疗为风险驱动和对症处理,尚无标准方案。
- 造血干细胞移植是唯一可能治愈的手段,应考虑用于符合条件的患者。
- 近期遗传学分析发现CBL、CEBPA、EZH2、NRAS、TET2和U2AF1为两者高危突变,NRAS/KRAS和ETNK1等可靶向突变支持针对相关通路的新药研究。
研究设计与样本
- 本文为综述,汇总2022年WHO和ICC分类标准、遗传学特征、风险分层模型及管理策略。
- 文中详细描述了Mayo Clinic CNL和aCML风险模型及正在评估的新药(如fedratinib,2期)临床研究。
主要发现
- CNL诊断需白细胞≥25×10⁹/L、中性粒细胞≥80%且循环前体细胞<10%、无病态造血及CSF3R激活突变。
- ICC标准中CSF3R突变病例的白细胞阈值降至≥13×10⁹/L;aCML需白细胞≥13×10⁹/L、病态粒细胞生成、循环髓系前体细胞≥10%及至少一系血细胞减少(ICC的MDS阈值)。
- CNL分子标志为CSF3R突变(经典T618I),见于>80%病例;aCML常伴ASXL1、SETBP1、TET2、SRSF2、EZH2突变,ETNK1较少见。
- CNL和aCML的白血病转化率分别约10-25%和30-40%,总生存期分别为15-31个月和12-20个月。
- Mayo Clinic CNL风险模型:血小板<160×10⁹/L(2分)、白细胞>60×10⁹/L(1分)、ASXL1突变(1分),低危(0-1分)vs高危(2-4分);aCML模型:年龄>67岁、血红蛋白<10 g/dL、TET2突变各1分,低危(0-1个危险因素)vs高危(≥2个危险因素)。
关键数值与推荐
- WHO(2022)CNL诊断标准:白细胞≥25×10⁹/L、中性粒细胞≥80%且循环前体细胞<10%、无病态造血、存在CSF3R激活突变。
- ICC标准中CSF3R突变病例的白细胞阈值≥13×10⁹/L;aCML诊断需白细胞≥13×10⁹/L、病态粒细胞生成、循环髓系前体细胞≥10%及至少一系血细胞减少(MDS阈值)。
- 两种分类中ASXL1和SETBP1(ICC)或SETBP1±ETNK1(WHO)突变可用于支持诊断。
- Mayo Clinic CNL风险模型:血小板<160×10⁹/L(2分)、白细胞>60×10⁹/L(1分)、ASXL1突变(1分),低危(0-1分)vs高危(2-4分)。
- Mayo Clinic aCML风险模型:年龄>67岁、血红蛋白<10 g/dL、TET2突变各1分,低危(0-1个危险因素)vs高危(≥2个危险因素)。
临床怎么用
- 管理为风险驱动和对症处理,目前无标准治疗方案。
- 最常用药物包括羟基脲、干扰素、Janus激酶抑制剂和去甲基化药物,但均非疾病修饰。
- 造血干细胞移植是唯一可能治愈的手段,应考虑用于符合条件的患者。
- 针对可靶向突变(NRAS/KRAS、ETNK1)的新药(如fedratinib,2期)及联合方案正在临床研究中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic neutrophilic leukemia (CNL) is a rare BCR::ABL1-negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic "[MDS]/MPN with neutrophilia" per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death. The 2022 revised WHO classification conserved CNL diagnostic criteria of leukocytosis ≥25 × 109/L, neutrophils ≥80% with <10% circulating precursors, absence of dysplasia, and presence of an activating CSF3R mutation. ICC criteria are harmonized with those of other myeloid entities, with a key distinction being lower leukocytosis threshold (≥13 × 109/L) for cases CSF3R-mutated. Criteria for aCML include leukocytosis ≥13 × 109/L, dysgranulopoiesis, circulating myeloid precursors ≥10%, and at least one cytopenia for MDS-thresholds (ICC). In both classifications ASXL1 and SETBP1 (ICC), or SETBP1 ± ETNK1 (WHO) mutations can be used to support the diagnosis. Both diseases show hypercellular bone marrow due to a granulocytic proliferation, aCML distinguished by dysplasia in granulocytes ± other lineages. Absence of monocytosis, rare/no basophilia, or eosinophilia, <20% blasts, and exclusion of other MPN, MDS/MPN, and tyrosine kinase fusions, are mandated. Cytogenetic abnormalities are identified in ~1/3 of CNL and ~15-40% of aCML patients. The molecular signature of CNL is a driver mutation in colony-stimulating factor 3 receptor-classically T618I, documented in >80% of cases. Atypical CML harbors a complex genomic backdrop with high rates of recurrent somatic mutations in ASXL1, SETBP1, TET2, SRSF2, EZH2, and less frequently in ETNK1. Leukemic transformation rates are ~10-25% and 30-40% for CNL and aCML, respectively. Overall survival is poor: 15-31 months in CNL and 12-20 months in aCML. The Mayo Clinic CNL risk model for survival stratifies patients according to platelets <160 × 109/L (2 points), leukocytes >60 × 109/L (1 point), and ASXL1 mutation (1 point); distinguishing low- (0-1 points) versus high-risk (2-4 points) categories. The Mayo Clinic aCML risk model attributes 1 point each for: age >67 years, hemoglobin <10 g/dL, and TET2 mutation, delineating low- (0-1 risk factor) and high-risk (≥2 risk factors) subgroups. Management is risk-driven and symptom-directed, with no current standard of care. Most commonly used agents include hydroxyurea, interferon, Janus kinase inhibitors, and hypomethylating agents, though none are disease-modifying. Hematopoietic stem cell transplant is the only potentially curative modality and should be considered in eligible patients. Recent genetic profiling has disclosed CBL, CEBPA, EZH2, NRAS, TET2, and U2AF1 to represent high-risk mutations in both entities. Actionable mutations (NRAS/KRAS, ETNK1) have also been identified, supporting novel agents targeting involved pathways. Preclinical and clinical studies evaluating new drugs (e.g., fedratinib, phase 2) and combinations are detailed.
引用
- Szuber N, Orazi A, Tefferi A, et al. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Am J Hematol. 2024. PMID: 38644693. doi:10.1002/ajh.27321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。